Eyepoint Pharmaceuticals Inc
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | +0.0% | -132.0% | – | – | – | +0.0% | -258.5% | – | – | – | – | – | – | – | -6,832.1% | – | |
| – | +13.6% | +415.4% | +0.0% | +786.9% | -20.8% | -95.4% | +737.8% | +0.9% | -33.6% | -55.4% | -7.7% | -3.8% | +2.9% | -10.2% | +0.0% | +40.9% | +126.8% | +1.7% | +4.6% | -11.7% | -81.0% | +231.9% | +49.9% | |
| – | – | – | – | – | -2.2% | -101.7% | – | +37.3% | -31.2% | -6.7% | +7.1% | +39.0% | +10.3% | +13.5% | +0.0% | +61.5% | +15.1% | +21.4% | +34.3% | +90.4% | -15.0% | +204.7% | -24.1% | |
| – | – | – | – | – | – | – | – | – | – | -91.8% | +1.2% | +47.1% | +10.3% | +13.5% | +1,080.0% | +69.5% | -80.8% | -21.2% | -10.4% | +476.3% | – | – | – | |
| – | -230.8% | – | – | -53.2% | +1,055.9% | -177.7% | – | – | – | -42.9% | -43.8% | +159.4% | +105.5% | -84.7% | -22.0% | -479.0% | – | – | -108.6% | – | – | -147.2% | – | |
| – | +929.7% | +606.9% | +0.0% | -55.4% | -92.9% | +231.7% | -28.3% | -92.3% | +786.7% | +204.5% | -83.2% | +264.7% | -35.1% | -29.8% | +30.1% | -26.5% | +97.2% | +70.0% | -56.9% | +1,278.2% | +62.0% | +16.3% | -19.1% | |
| – | +949.7% | – | – | 0.0% | – | -114.6% | +698.8% | +359.1% | – | +949.2% | -99.0% | +0.0% | -6,860.6% | – | -224.4% | +0.0% | -98.7% | +70.0% | +9,049.4% | -47.9% | -80.8% | +6,517.0% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | +3,995.6% | -78.9% | -76.2% | +7,129.8% | -50.0% | +394.2% | -100.5% | -32.8% | -31.3% | +66.7% | +96.7% | -42.7% | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | +0.0% | +0.0% | -6.7% | +7.2% | +29.7% | -156.4% | -99.0% | +347.3% | +6,103.8% | -99.7% | +0.0% | |
| – | +382.5% | +0.0% | +693.9% | -1.3% | -15.1% | +0.0% | -95.6% | +1,154.4% | +0.0% | -53.6% | +307.9% | +0.0% | -10.8% | -50.0% | +0.0% | +243.5% | +16.0% | +10.7% | +478.5% | -100.3% | – | -12.3% | +5.9% | |
| – | – | -166.9% | – | – | -650.0% | – | -167.3% | – | -130.2% | – | – | +270.9% | -55.1% | -200.6% | – | +1,280.3% | -205.3% | – | +489.0% | -162.1% | – | -197.8% | – | |
| – | – | – | – | – | – | – | – | – | -133.4% | – | – | – | – | -262.1% | – | – | – | – | – | – | – | – | – |
Data as of: October 6, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.